These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30447530)

  • 41. Real-world results with IgPro20 for hypo- or agammaglobulinemia in Japan.
    Imai K; Ishii T; Nonoyama S; Yasumi T; Kanegane H; Fukushima T; Matsumaru M; Akasaki T; Usui H
    Pediatr Int; 2022 Jan; 64(1):e15362. PubMed ID: 36151913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of intravenous immunoglobulin G (IVIG).
    Looney RJ; Huggins J
    Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.
    Simão-Gurge RM; Costa-Carvalho BT; Nobre FA; Gonzalez IG; de Moraes-Pinto MI
    Allergol Immunopathol (Madr); 2017; 45(1):55-62. PubMed ID: 27480789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
    Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
    Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
    Ballow M
    Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):22-5. PubMed ID: 19630866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
    Agostini C; Blau IW; Kimby E; Plesner T
    Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.
    Mahmood I; Li Z
    Immunotherapy; 2024; 16(13):879-894. PubMed ID: 39323402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunoglobulins in PID, SID and neurological autoimmune disease].
    Borte M; Baumann U; Pittrow D; Hensel M; Fasshauer M; Huscher D; Reiser M; Stangel M; Gold R; Kirch W;
    Dtsch Med Wochenschr; 2012 Mar; 137(13):675-80. PubMed ID: 22434180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.
    Bonagura VR
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S90-4. PubMed ID: 23271459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
    Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
    Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.
    Kaveri SV; Maddur MS; Hegde P; Lacroix-Desmazes S; Bayry J
    Clin Exp Immunol; 2011 Jun; 164 Suppl 2(Suppl 2):2-5. PubMed ID: 21466545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.
    Robak T; Salama A; Kovaleva L; Vyhovska Y; Davies SV; Mazzucconi MG; Zenker O; Kiessling P;
    Hematology; 2009 Aug; 14(4):227-36. PubMed ID: 19635187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behavior abnormality following intravenous immunoglobulin treatment in patients with primary antibody deficiencies.
    Saroukhani S; Aghamohammadi A; Mahmoudi-Gharaei J; Abolhassani H; Cheraghi T; Imanzaeh A; Moazzami K; Parvaneh N; Rezaei N
    Hum Psychopharmacol; 2010 Jul; 25(5):419-22. PubMed ID: 20589928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
    Berger M; Murphy E; Riley P; Bergman GE;
    South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serial Serum Immunoglobulin G (IgG) Trough Levels in Patients with X-linked Agammaglobulinemia on Replacement Therapy with Intravenous Immunoglobulin: Its Correlation with Infections in Indian Children.
    Suri D; Bhattad S; Sharma A; Gupta A; Rawat A; Sehgal S; Singh S; Gupta S
    J Clin Immunol; 2017 Apr; 37(3):311-318. PubMed ID: 28321612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetic modelling of intravenous immunoglobulin in patients with predominantly antibody deficiencies.
    Lee JL; Mohd Saffian S; Makmor-Bakry M; Islahudin F; Alias H; Noh LM; Ismail IH; Mohamed Shah N
    Br J Clin Pharmacol; 2021 Jul; 87(7):2956-2966. PubMed ID: 33377197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
    Bauhofer A; Dietrich RL; Schmeidl R
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
    Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
    Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.